Evidence map›Paper›PMID 34416081›Full record

ArticleJournal of cosmetic dermatology2022

Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole.

Philippe Massiot, Cécile Clavaud, Marie Thomas, Alban Ott, Audrey Guéniche, Ségolène Panhard, Benoît Muller, Céline Michelin, Delphine Kerob, Anne Bouloc and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. A bibliometric and visual analysis of the research status and hotspots of seborrheic dermatitis based on web of science.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Philippe MassiotL'Oréal Research & Innovation, Saint-Ouen, France.
Cécile ClavaudL'Oréal Research & Innovation, Aulnay-sous-Bois, France.
Marie ThomasL'Oréal Research & Innovation, Aulnay-sous-Bois, France.
Alban OttL'Oréal Research & Innovation, Aulnay-sous-Bois, France.
Audrey GuénicheL'Oréal Research & Innovation, Chevilly-Larue, France.
Ségolène PanhardL'Oréal Research & Innovation, Saint-Ouen, France.
Benoît MullerL'Oréal Research & Innovation, Saint-Ouen, France.
Céline MichelinL'Oréal Research & Innovation, Saint-Ouen, France.
Delphine KerobVichy Laboratoires, Levallois-Perret, France.
Anne BoulocVichy Laboratoires, Levallois-Perret, France.
Pascal ReygagneCentre Sabouraud, Paris, France.
L'Oréal (France) · FRHoneywell (France) · FRInstitut Européen De La Qualité Totale · FRLaboratoire Dr Renaud · FR

Funding

Laboratoires Vichy
6 · The paper itself

Abstract

objectiveScalp seborrheic dermatitis (SD) is a chronic, relapsing, and inflammatory scalp disease. Studies indicate a global bacterial and fungal microbiota shift of scalp SD, as compared to healthy scalp. Ketoconazole and selenium disulfide (SeS

aimThe main objective of this study was to investigate the changes in the scalp microbiota diversity and counts in subjects with scalp SD during a two-phase treatment period. MATERIAL AND

methodsThe scalp microbiota and clinical efficacy were investigated in 68 subjects with mild-to-moderate scalp SD after an initial one-month treatment with 2% ketoconazole, and after a 2-month maintenance phase, either with a 1% SeS

resultsThirty one subjects in the active and 37 subjects in the vehicle group participated. Ketoconazole provided an improvement of clinical symptoms (adherent (-1.75 p < 0.05), non-adherent (-1.5, p < 0.05)) flakes and erythema (scores 1.67-0.93, p < 0.001), in an increased fungal diversity and in a significant (p < 0.005) decrease of Malassezia spp. SeS

conclusionSelenium disulfide provides an additional benefit on the scalp microbiota and in clinical symptoms of SD and dandruff after treatment with ketoconazole. The results confirm the role of Staphylococcus spp. in scalp SD and open possible perspectives for preventing relapses.

Indexed as

DandruffDermatitis, SeborrheicHair PreparationsMalasseziaMicrobiotaScalp DermatosesHumansKetoconazoleScalpSelenium CompoundsHair PreparationsKetoconazoleSelenium Compoundsselenium disulfideketoconazolescalp microbiotaseborrheic dermatitisselenium disulfide

Identifiers

PMID34416081
PMCPMC10234447
OpenAlexW3194555897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.